Key result
Intravenous quinidine significantly increased right ventricular outflow tract monophasic action potential duration (261.7 vs 225.3 ms) and suppressed the induction of ventricular fibrillation in 5 of 6 patients with Brugada syndrome.
Why the study?
Does intravenous quinidine alter RVOT action potential duration restitution kinetics and suppress inducible ventricular fibrillation in patients with Brugada syndrome?
Observational (n=9)
No
Does intravenous quinidine alter RVOT action potential duration restitution kinetics and suppress inducible ventricular fibrillation in patients with Brugada syndrome?
Intravenous quinidine alters RVOT action potential duration restitution kinetics and suppresses the induction of ventricular fibrillation in patients with Brugada syndrome.
Should not change practice; hypothesis-generating for quinidine in Brugada syndrome and requires prospective validation.
BACKGROUND: On a cellular level, Brugada syndrome has been attributed to a deep phase 1 notch and subsequent shallow and prolonged repolarization in the right ventricular outflow tract (RVOT). A sodium channel mutation that leads to early inactivation of the late sodium current has been identified in some patients. Thus, drugs that inhibit the transient outward current (I(to)) responsible for the phase 1 notch and/or enhance the late sodium current might suppress arrhythmic events in patients with Brugada syndrome. The effects of quinidine gluconate, a potent inhibitor of I(to), on RVOT action potential duration (APD) restitution kinetics in patients with Brugada syndrome were evaluated. METHODS AND RESULTS: Programmed ventricular stimulation was performed in 9 Brugada syndrome patients by delivering up to 3 extrastimuli from the right ventricular apex and RVOT. RVOT monophasic action potentials (MAPs) were recorded before and after intravenous administration of quinidine (n=6) or ibutilide (n=3). All patients had inducible ventricular fibrillation (VF) before drug administration. Both quinidine and ibutilide increased steady-state and minimum RVOT MAP duration during programmed stimulation. Quinidine decreased the maximum slope of the RVOT APD restitution curve and VF could not be induced after administration of quinidine in 5 of the 6 patients. CONCLUSIONS: Quinidine appears to suppress the induction of VF by increasing RVOT MAP duration and decreasing the maximum slope of the restitution curve.
No takes yet. Share an insight, caveat, or question.
Ashino et al. (2011) conducted an observational in Brugada syndrome with inducible ventricular fibrillation (n=9). Quinidine vs. Baseline (pre-administration) was evaluated on Right ventricular outflow tract monophasic action potential duration at 90% repolarization (RVOT MAPD90) (p=0.0277). Intravenous quinidine significantly increased right ventricular outflow tract monophasic action potential duration (261.7 vs 225.3 ms) and suppressed the induction of ventricular fibrillation in 5 of 6 patients with Brugada syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: